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Opioids are the most common drugs associated with unintentional drug overdose. Death results from respiratory depression. Prolonged
use of opioids results in the development of tolerance but the degree of tolerance is thought to vary between different effects of the drugs.
Many opioid addicts regularly consume alcohol (ethanol), and post-mortem analyses of opioid overdose deaths have revealed an inverse
correlation between blood morphine and ethanol levels. In the present study, we determined whether ethanol reduced tolerance to the
respiratory depressant effects of opioids. Mice were treated with opioids (morphine, methadone, or buprenorphine) for up to 6 days.
Respiration was measured in freely moving animals breathing 5% CO2 in air in plethysmograph chambers. Antinociception (analgesia) was
measured as the latency to remove the tail from a thermal stimulus. Opioid tolerance was assessed by measuring the response to a
challenge dose of morphine (10 mg/kg i.p.). Tolerance developed to the respiratory depressant effect of morphine but at a slower rate than
tolerance to its antinociceptive effect. A low dose of ethanol (0.3 mg/kg) alone did not depress respiration but in prolonged morphine-
treated animals respiratory depression was observed when ethanol was co-administered with the morphine challenge. Ethanol did not alter
the brain levels of morphine. In contrast, in methadone- or buprenorphine-treated animals no respiratory depression was observed when
ethanol was co-administered along with the morphine challenge. As heroin is converted to morphine in man, selective reversal of
morphine tolerance by ethanol may be a contributory factor in heroin overdose deaths.
Neuropsychopharmacology (2016) 41, 762–773; doi:10.1038/npp.2015.201; published online 9 September 2015
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INTRODUCTION
Overdose is the most common cause of accidental death for
opiate dependent users, especially if the drugs are injected
(Mathers et al, 2013; Pierce et al, 2015). Death in opioid
overdose results primarily from respiratory depression
(White and Irvine, 1999). Chronic opioid use results in the
development of tolerance such that larger doses are required
by an opioid addict to obtain their effects. It has been
suggested that tolerance to respiratory depression is less
pronounced than to other effects such as euphoria (White
and Irvine, 1999). Surprisingly, levels of heroin and its
metabolites in overdose victims are often lower than that
expected in highly tolerant individuals (Darke et al, 2002).
This has been interpreted as the victims having taken their
normal dose of heroin during a period of reduced tolerance,
such as that occurring after incarceration or detoxification,
with the drug then inducing greater respiratory depression
than expected (White and Irvine, 1999).
Heroin addicts are notorious polydrug users, with alcohol
(ethanol), cocaine, benzodiazepines, and amphetamine use
reported by heroin users and observed in heroin overdose
post-mortem analyses (Darke and Hall, 2003; Hickman et al,
2007). Ethanol is the most common drug found along with
opioids in overdose victims across several countries, though
the levels of ethanol found are rarely high (Darke and Hall,
2003; Hickman et al, 2007; Shah et al, 2008; Green et al, 2011;
Fugelstad et al, 2014). Furthermore, post-mortem analyses
have revealed an inverse relationship between heroin and
blood ethanol content (Ruttenber et al, 1990; Levine et al,
1995; Fugelstad et al, 2003).
The prevailing clinical and epidemiological interpretation
of these data is that ethanol and heroin mutually re-inforce
each other in order to increase the risk of respiratory
depression, though other explanations are possible (see
Hickman et al, 2008). We have focused our research on an
alternative hypothesis that ethanol might lower the level of
opioid tolerance thus increasing the propensity for overdose.
We have reported previously that low doses of ethanol
reverse the tolerance induced by prolonged exposure to mor-
phine both at the level of single brain neurons (Llorente et al,
2013) and in rodent antinociception tests (Hull et al, 2013).
In the present study, we have gone on to characterize in mice
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the development of tolerance to the respiratory depressant
effects of three opioids that are important with regard to the
abuse and maintenance treatment of opioid addiction—
morphine (heroin is rapidly converted to morphine in the
body), methadone and buprenorphine—and have examined
the ability of low doses of ethanol to reverse such tolerance.
We have found that tolerance to the respiratory depressant
effect of morphine develops more slowly than the well-
documented tolerance that develops to its antinociceptive
(analgesic) effect—as hypothesized by White and Irvine
(1999). Ethanol reversed morphine-induced tolerance to
respiratory depression but not that induced by prolonged
administration of methadone. Furthermore, ethanol did
not reverse the blockade of morphine-induced respiratory
depression produced by prolonged treatment with
buprenorphine.
MATERIALS AND METHODS
Animals
Male CD-1 mice (Harlan Laboratories, UK) weighing ~ 30 g
were maintained at 22°C on a reversed 12-h dark : light cycle
with food and water available ad libitum. All experiments
were performed in the dark (active) phase. All procedures
were performed in accordance with the UK Animals
(Scientific Procedures) Act 1986, the European Communities
Council Directive 1986 (86/609/EEC) and the University of
Bristol ethical review document.
Measurement of Respiration
Respiration was measured in freely moving animals using
plethysmography chambers equipped with differential pressure
transducers connected through an interface (emka Technolo-
gies, France) to a computer for recording and analysis of
respiration parameters. The chambers were supplied with
either room air via a pump or cylinder fed a 5% CO2 in air
gas mixture (BOC Industrial Gases, UK). Rate and depth of
respiration were recorded and converted to minute volume.
The average minute volume was calculated over 5-min bins.
Mice were habituated to the plethysmography chambers
on the day before an experiment. This lasted for 30 min with
mice breathing air. On the experimental day, baseline minute
volume was measured for all mice breathing 5% CO2 in air
over a 20-min period. Challenge drugs were injected
intraperitoneally (i.p.) in a 5-min window after the baseline
measurement and mice returned to the plethysmograph
chambers. Minute volume in 5% CO2 in air was then
recorded for a further 30 min following drug administration.
Changes in minute volume were used to assess respiratory
depression following acute drug administration. For each
mouse the change in minute volume following acute drug
administration was calculated as the percentage of the pre-
drug baseline.
Measurement of Nociception
Mice were hand held, the tails immersed approximately one
inch in water at 52.5°C and the latency until the tail was
removed from the water measured. On the experimental day,
baseline tail-flick latency was recorded prior to drug
administration and then measured every 15 min for 1 h.
A cutoff time of 20 s was used to prevent thermal damage to
the tail.
Induction of Opioid Tolerance
A 75-mg morphine alkaloid pellet or placebo pellet was
implanted subcutaneously on the lower dorsal flank under
isoflurane general anesthesia. We found no differences in the
responses of placebo pellet-implanted mice and naive mice.
Hence, to reduce the number of animals undergoing surgery
the control animals in Figure 3c and d and Figure 4b were
naive mice rather than placebo pellet-implanted mice. In one
series of experiments morphine tolerance was induced by
repeated injections with mice receiving two 10mg/kg
morphine injections 12 h apart daily for 5 days. For
buprenorphine and methadone, osmotic mini-pumps (AL-
ZET) containing either buprenorphine (6.25 mg/ml deliver-
ing 5 mg/kg/day), methadone (75 mg/ml delivering 60 mg/
kg/day), or vehicle (saline) were implanted on the dorsal
flank under isoflurane general anesthesia. As described
previously, to enhance the induction of tolerance to
methadone (Quillinan et al, 2011) mice received a 5 and
7.5 mg/kg injection of methadone 12 h apart on the day prior
to, and an injection of 7.5 mg/kg of methadone on the
morning of pump implantation.
Measurement of Brain and Plasma Morphine Levels
Mice were killed using escalating CO2 and blood samples
collected from the descending abdominal aorta. Blood
samples were centrifuged at 3000 g for 10 min at 4°C and
the aliquoted plasma supernatant stored at − 20°C. Approxi-
mately, 100 μl of each plasma supernatant was mixed
thoroughly with 500 μl acetonitrile containing 200 ng/ml of
deuterated morphine as internal standard and centrifuged at
13 000 r.p.m. for 10 min at room temperature. Approxi-
mately, 300 μl of samples of the supernatant were evaporated
to dryness using a speed vac.
Immediately after blood sampling, mice were decapitated
and the head placed on ice. After removal from the skull, the
brains were flash frozen in liquid nitrogen before storage
at − 80°C. Brains were homogenized in phosphate buffer
solution added at a ratio of 2 ml per gram of brain matter.
Approximately, 100 μl of aliquots of brain homogenate
samples were mixed thoroughly with 500 μl acetonitrile
containing 200 ng/ml of deuterated morphine as internal
standard and extracted as described for plasma samples.
Brain and plasma samples were reconstituted in acetonitrile/
H2O (20/80) and analyzed by liquid chromatography (Ultimate
3000 LC system, Dionex, USA)/tandem mass spectrometry
(Q Exactive Orbitrap, Thermo Scientific, USA). Samples were
analyzed in positive ion mode for morphine, hydromorphone,
and morphine-3-glucuronide (M-3-G), the major metabolite
of morphine in mice (Kuo et al, 1991). The quantification
range for morphine was between 2.0 and 20 000 ng/ml.
Hydromorphone was not found in any of the samples.
Measurement of Plasma Corticosterone Levels
Mice were killed by cervical dislocation, decapitated, and
trunk blood collected. Approximately, 100 μl of 100 units/ml
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of heparin were added to each blood sample to prevent
coagulation. Samples were then centrifuged at 3000 g for
10 min at 4°C, and the supernatant was removed and stored
at − 20°C prior to analysis. Corticosterone concentrations
in the plasma were quantified by radioimmunoassay as
previously described (Waite et al, 2012) using a cortico-
sterone antibody (supplied by G Makara, Institute of
Experimental Medicine, Budapest, Hungary).
Measurement of Mouse Locomotion
A beam break rig (Linton Instrumentation, UK) was used
to assess the locomotor activity of mice. An automated
data logging suite (AMON Lite, Linton Instrumentation,
UK) was used to track the movement of mice throughout
the experimental session. On the day prior to locomotor
assessment each mouse was placed in a fresh cage and
allowed to explore the cage for 30 min. On the experimental
day, the mouse was again allowed to explore the cage for
30 min before drug administration. Locomotion was then
measured for 30 min following drug administration. Mice
had access to water ad libitum but had no access to food in
either session in order to dissuade rearing and climbing
behavior.
Data Analysis
Area under the curve (AUC) was determined using a 100%
baseline. Overall changes from a single factor (ie, drug)
were analyzed using a one-way ANOVA with Bonferroni’s
post-test. Interaction between prolonged drug treatment
(±morphine pellet or osmotic mini-pump) and challenge
drug was analyzed using a two-way ANOVA in a two-by-two
factorial. Changes in groups over time with repeat measure-
ments were analyzed using a two-way repeated measures
ANOVA with Bonferroni’s post-test to analyze drug effect
over time. GraphPad Prism 4 was used for all statistical
analyses. All data are displayed as mean± SEM.
Drugs and Chemicals
Buprenorphine hydrochloride (Tocris, UK), ethanol (Sigma-
Aldrich, UK), methadone hydrochloride (Sigma-Aldrich,
UK), and morphine hydrochloride (Macfarlane Smith) were
dissolved in sterile saline. 75 mg morphine alkaloid pellets
and placebo pellets were obtained from the National Institute
on Drug Abuse (Bethesda, MD). Heparin (Sigma-Aldrich,
UK) was dissolved in distilled water.
RESULTS
Morphine-Induced Respiratory Depression
We have studied the effects of morphine on mice breathing
5% CO2 in air. In this gas mixture, respiration (tidal volume,
not rate) is elevated over that observed when animals
breathed air alone (Table 1), but remained at a constant level
throughout the period of testing up to 1 h (Figure 1a).
Administration of morphine (3–30 mg/kg i.p.) produced
significant dose-dependent depression of respiration, which
developed rapidly within 5 min of drug injection, and was
maintained for the remainder (30 min) of the observation
period (Figure 1a–c). The depression of respiration resulted
from both a decrease in rate and depth of respiration
(compare experimental traces in Figure 1d and e), but there
was no decrease in tidal volume (Table 2) as the duration
of inspiration was increased. As the experiments were
performed in 5% CO2 in air, it is not possible to tell if the
decrease in minute volume induced by morphine is due to an
action on respiratory rate generation or on chemoreflexes.
Mice did not exhibit ribcage muscle stiffness, which would
reduce tidal volume. As can be seen in Figure 1c, all mice
tested responded to morphine with a decrease in respiration,
we did not observe any morphine-insensitive animals.
Morphine is known to induce locomotor activity in
mice (Lessov and Phillips, 2003; Valjent et al, 2010) and as
this would likely increase respiration, it could mask the
respiratory depressant actions of the drug, especially at
high doses. Therefore, in a separate series of experiments,
we measured locomotor activity for 30 min after morphine
(10–30 mg/kg) injection (Figure 1f). Only at 30 mg/kg did
morphine increase locomotor activity. For this reason, we
have chosen in our subsequent experiments to use a dose of
10 mg/kg morphine as the challenge dose, as the results
would not be confounded by any change in locomotor
activity.
One possibility that we wished to exclude was that having
the animals breathing 5% CO2 in air might induce stress and
that the depression of respiration was due to an antianxiety
effect of morphine, not a direct effect on respiration. We
therefore measured plasma corticosterone levels in animals
that had breathed air or 5% CO2 in air for 30 min. Plasma
corticosterone levels have been shown to rise when animals
are stressed (Aliczki et al, 2013; Sakakibara et al, 2010). There
was no difference in the plasma corticosterone levels in
animals breathing air or 5% CO2 in air (233.7± 23.1 and
229.2± 34.6 ng/ml, respectively, N= 10). Furthermore, when
animals breathing 5% CO2 in air were administered
morphine (10 mg/kg), there was no significant decrease in
plasma corticosterone levels (177.4± 20.7 ng/ml, N= 10, data
were compared using one-way ANOVA with Bonferroni’s
comparison). These results indicate that morphine depressed
respiration directly and not through an indirect anxiolytic
mechanism.
Induction of Morphine Tolerance
To induce tolerance to morphine, we exposed animals to
morphine continuously for up to 6 days by implanting a
morphine pellet (75 mg) subcutaneously. Animals that had
Table 1 Comparison of Respiration Parameters in Mice Breathing
Air or 5% CO2 in Air
Gas Minute volume
(MV; ml/min)
Frequency
(F; BPM)
Tidal volume
(TV; ml/breath)
N
Air 79.2± 13.9 414.0± 69.8 0.19± 0.01 8
5% CO2 in air 148.2
a± 7.0 426.9± 10.1 0.35a± 0.01 8
All values are mean± SEM of 5-min averages taken from the 15–20-min time bin
following exposure to air or 5% CO2 in air in the plethysmograph chamber.
aIndicates significant difference (po0.05) from air. Values were compared using
an unpaired Student’s t-test.
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been implanted with a morphine pellet showed significant
respiratory depression (Figure 2a) as well as antinociception
in the tail-flick latency test (Figure 2b) when tested 1 day
later, whereas those animals that received a placebo pellet did
not. Although the depression of respiration declined on
subsequent days, it did not reach pre-pellet levels until 5 days
after pellet implantation even though the levels of
morphine in the brain and plasma were still elevated
(Figure 2c and d). The plasma level of morphine after 6 days
of pellet implantation was only slightly lower than that
achieved in naive mice following injection with 10 mg/kg
morphine (compare data in Figure 2c and d). After 6 days of
pellet implantation, mice did not show signs of spontaneous
withdrawal such as diarrhea or jumping.
In contrast to respiratory depression, tail-flick latencies
returned to baseline 2 days after pellet implantation at a time
when plasma morphine levels were still raised (Figure 2d).
This suggests that tolerance develops to the antinociceptive
effects of morphine more rapidly than to its respiratory
depressant effect.
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Figure 1 Morphine depression of mouse respiration. (a–c) Morphine (3–30 mg/kg) dose-dependently depressed mouse respiration. In (a) data are
presented as minute volume, whereas in (b) the percentage change in minute volume following drug injection for each animal has been normalized to the pre-
drug control level before the mean change was calculated. In (c) the area under the curve (AUC) for the percentage change in minute volume has been
calculated for each individual animal before the mean AUC has been calculated. N= 8 for all groups. F= 23.17, 3 mg/kg, po0.05; 10–30 mg/kg, po0.001.
(d, e) Raw respiration traces recorded from a single mouse in each case. The horizontal blue line indicates the point of pressure inflection. On the respiration
traces expiration is upwards. (f) Morphine 30 mg/kg caused a significant increase in locomotor activity, whereas 10 mg/kg morphine did not. N= 10 for all
groups. F= 7.83, po0.01. All drugs administered i.p. Data are expressed as mean± SEM and were analyzed using one-way ANOVA with Bonferroni’s
comparison. *Indicates significant difference (po0.05).
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To investigate further the different time courses of
tolerance development between the respiratory depressant
and antinociceptive effects of morphine, we injected mice
twice daily with morphine (10 mg/kg i.p.) for 5 days and
measured respiration and tail-flick latency after the second
injection on each day (Figure 2e and f). The injection of
morphine produced a lower brain level of morphine than
morphine pellet implantation (Figure 2c). This protocol
produced significant tolerance to morphine-induced anti-
nociception by day 3 (Figure 2f), but tolerance to the
respiratory depressant effect of morphine did not develop
(Figure 2e). Taken together, these results demonstrate a
differential development of tolerance to morphine-induced
respiratory depression and antinociception.
To facilitate quantification of the level of tolerance to
respiratory depression after prolonged (6 days) morphine
exposure, we measured the degree of respiratory depression
in response to an acute challenge dose of morphine. Mice
implanted with a 75-mg morphine pellet for 6 days exhibited
a significantly reduced depression of respiration following an
acute dose of morphine (10 mg/kg i.p.) on day 6 compared
to placebo pellet-implanted mice (Figure 3a and b). Mice
implanted with the morphine pellet for 6 days also showed
tolerance to the antinociceptive effect of the acute challenge
with morphine (Figure 3c). The decreased respiratory
depressant effect of morphine after prolonged morphine
treatment was not due to the animals becoming sensitized to
the locomotor effect of the acute challenge with morphine
(10 mg/kg) as locomotor activity remained unchanged
(Figure 3d).
Ethanol Reversal of Morphine Tolerance
To investigate the effect of ethanol on morphine tolerance,
we gave mice an acute injection of ethanol along with the
challenge dose of morphine. We first demonstrated that a
low dose of ethanol (0.3 g/kg i.p.) alone did not depress
respiration in naive mice or mice that had been implanted
with a morphine pellet for 6 days (Figure 4). Furthermore,
ethanol (0.3 g/kg i.p.) did not enhance the respiratory
depressant effect of the acute morphine (10 mg/kg) challenge
(Figure 4b). Higher doses of ethanol (41 g/kg) did depress
respiration in naive mice (data not shown). When mice that
had been implanted with a morphine pellet for 6 days
received an injection of ethanol (0.3 mg/kg) at the same time
as the morphine challenge then morphine now significantly
suppressed respiration by reducing respiratory rate (Table 2).
This is consistent with an ethanol reversal of morphine
tolerance, in that the animals showed significantly greater
respiratory depression in response to the acute challenge
with morphine (10 mg/kg) than those morphine pellet-
implanted mice that received either morphine or ethanol
alone (Figure 4a and b). When ethanol (0.3 mg/kg) was
administered to morphine pellet-implanted mice 6 h before
the morphine challenge then no reversal of tolerance was
observed indicating that the reversal of tolerance by ethanol
is transient. Ethanol (0.3 g/kg), alone or in combination with
morphine (10 mg/kg) did not significantly alter locomotor
activity in naive mice or mice that had been implanted with a
morphine pellet for 6 days (Figure 4c and d).
Lack of Effect of Ethanol on Morphine Levels in the
Brain and Plasma
We next determined the concentration of morphine and
its major metabolite M-3-G in the brain and plasma of
morphine-treated mice (Figure 5). In morphine pellet-
implanted animals the plasma level of M-3-G was ~ 20 times
that of morphine, whereas in the brain the concentrations
were similar (data not shown). In animals that had been
treated with morphine for 6 days, ethanol (0.3 g/kg)
administered along with a challenge dose of morphine
(10 mg/kg) did not alter the brain concentration of morphine
(Figure 5). Thus the enhanced respiratory depressant
effect of morphine in morphine-treated mice seen on
co-administration of ethanol does not result from ethanol
increasing the brain concentration of morphine. This
suggests that ethanol reverses morphine tolerance rather
than increases morphine levels in the brain.
Table 2 Effect of Morphine Treatments on Respiratory Frequency and Tidal Volume in Mice Breathing 5% CO2 in Air
Pre-drug baseline 15Min post-drug
Drug Frequency (BPM) Tidal volume (ml/breath) Frequency (BPM) Tidal volume (ml/breath) N
Saline 377.4± 15.9 0.40± 0.02 341.3± 18.0 0.43± 0.03 8
Morphine 3 mg/kg 416.0± 29.6 0.38± 0.02 315.0± 25.1a 0.38± 0.02 8
Morphine 10 mg/kg 400.9± 21.0 0.37± 0.02 265.3± 12.1a 0.35± 0.01 8
Ethanol 0.3 g/kg 426.9± 10.1 0.41± 0.02 367.5± 16.2 0.46± 0.02 6
Morphine 10 mg/kg+ ethanol 0.3 g/kg 435.9± 21.6 0.36± 0.04 277.8± 11.4a 0.35± 0.02 6
MP–day 6 + saline 401.6± 11.5 0.38± 0.01 411.3± 16.1 0.39± 0.02 8
MP–day 6+morphine 10mg/kg 395.8± 27.0 0.40± 0.02 361.0± 32.1 0.41± 0.03 6
MP–day 6+morphine 10mg/kg + ethanol 0.3 g/kg 402.6± 13.4 0.44± 0.03 285.2± 8.3a 0.43± 0.03 6
All values are mean± SEM of 5-min averages. Pre-drug baseline values are taken from the 15–20-min pre-drug time bin. Post-drug values are taken from the 15–20-min
time bin taken from the time of injection. Unless otherwise stated there was no significant change from pre-drug baseline levels. MP= 75-mg morphine pellet. Values
were compared using a paired two-way Student’s t-test.
aIndicates a significant change (po0.05) from pre-drug baseline values.
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Lack of Effect of Ethanol following Chronic Treatment
with Methadone or Buprenorphine
After 6 days of methadone or buprenorphine treatment using
osmotic mini-pumps (see Materials and Methods), respira-
tion levels were similar to pre-pump implantation levels
(compare preinjection levels in Figure 1a and Figure 6a
and b). Following 6 days of methadone or buprenorphine
treatment, an acute challenge with morphine (10 mg/kg)
produced little respiratory depression (Figure 6). For metha-
done treatment, this likely reflects the development of
tolerance but with buprenorphine, which is a μ-opioid
Figure 2 Development of tolerance to the respiratory depressant and antinociceptive effects of morphine. (a) Following implantation of a 75-mg morphine
pellet respiratory depression was observed on days 1–4, before returning to baseline levels. F= 4.16, po0.001. (b) Following implantation of the morphine
pellet antinociception was only observed on day 1. F= 26.2, po0.001. In (a) and (b) control animals were implanted with a placebo pellet. (c) Plasma and
brain levels of morphine either 15 min after a morphine injection (10 mg/kg i.p.) or 6 days after implantation of a 75-mg morphine pellet. (d) Plasma levels of
morphine after implantation of a 75-mg morphine pellet. (e, f) With twice daily acute injections of morphine (10 mg/kg i.p.) no decrease (ie, tolerance) to the
respiratory depressant effect of morphine was observed over 5 days but tolerance to the antinociceptive effect of morphine had developed by day 3
(respiratory depression, F= 124.7, po0.001; antinociception, F= 7.90, po0.001). All drugs administered i.p. except for pellet implantation. Data are expressed
as mean± SEM and were analyzed using two-way repeated measures ANOVA with Bonferroni’s comparison. *Indicates significant difference (po0.05). N= 8
for (a–d) and 6 for (e, f).
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receptor (MOPr) partial agonist that dissociates slowly from
the receptors, we cannot discriminate between buprenor-
phine’s antagonist activity occluding the effect of the
morphine challenge and the development of tolerance.
In contrast to what was observed with morphine treat-
ment, in methadone- or buprenorphine-treated animals
co-administration of ethanol (0.3 g/kg) with the acute
morphine (10 mg/kg) challenge did not result in a significant
increase in the ability of morphine to depress respiration
(Figure 6a–d).
DISCUSSION
Morphine-induced respiratory depression, antinociception
(analgesia), and reward (a surrogate measure of euphoria in
animals) result from activation of MOPr as these behaviors
are not observed in the MOPr knockout mouse (Matthes
et al, 1996; Romberg et al, 2003). It has previously been
demonstrated that the development of tolerance to the
antinociceptive effect of morphine is greater with continuous
morphine exposure than with regular intermittent adminis-
tration (Dighe et al, 2009). In the present study, we observed
that with twice daily injections of morphine tolerance
developed to antinociception but not to respiratory
depression, whereas with continuous 6-day morphine
administration tolerance developed to both behaviors but
the tolerance to antinociception developed faster. McGilliard
and Takemori (1978) reported that respiratory depression
remained relatively unchanged while tolerance developed
to antinociception in mice receiving a combination of
morphine injections and pellet implantation but in their
study animals were only exposed to morphine for 3 days.
Tolerance to respiratory depression was not observed in
several other studies in which the duration of continuous
morphine administration was short (Ling et al, 1989) or
doses given once or twice daily (Paronis and Woods, 1997;
Kishioka et al, 2000).
On prolonged agonist exposure, the MOPr desensitizes
and this desensitization contributes to the development of
tolerance. The mechanisms responsible for MOPr desensi-
tization are agonist specific; for desensitization induced by
morphine, a relatively low-efficacy agonist, there is good
evidence for the involvement of protein kinase C (PKC; for
extensive review see Williams et al, 2013). We and others
have provided evidence that cellular tolerance to morphine
and tolerance to its antinociceptive effects are mediated by
PKC (Inoue and Ueda, 2000; Bohn et al, 2002; Smith et al,
2002; Bailey et al, 2006; Bailey et al, 2009a). The specific
isoforms of PKC thought to be involved in MOPr
Figure 3 Effect of acute morphine challenge after prolonged treatment with morphine. (a, b) Acute injection of morphine (10 mg/kg) produced significantly
less depression of respiration in mice that had been implanted for 6 days with a 75-mg morphine pellet (MP) than in mice implanted with a placebo pellet (PP).
Percentage change in minute volume and area under the curve (AUC) have been calculated as described for Figure 1. F= 13.13, po0.001. (c) Acute injection
of morphine (10 mg/kg) produced significantly less antinociception in mice that had been implanted with a morphine pellet for 6 days. F= 68.89, po0.001. (d)
Following 6 days of morphine pellet implantation there was no increase in locomotor activity in response to an acute injection of morphine (10 mg/kg). All
drugs administered i.p. (other than pellet implantation). Data are expressed as mean± SEM and were analyzed using two-way ANOVA with Bonferroni’s
comparison. *po0.05; N= 6 for all groups.
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desensitization and morphine tolerance are PKCα, PKCγ and
PKCε (Smith et al, 2007; Bailey et al, 2009b). The slower
development of tolerance to the respiratory depressant effect
of morphine may simply reflect low levels of PKC activity in
neurons that control respiration. Expression of constitutively
active PKCα or PKCε in the pre-Bötzinger complex, a group
of neurons involved in the generation of respiratory rhythm,
increased the development of tolerance to respiratory
depression by morphine induced by daily doses of morphine,
an effect that afforded increased protection to death by
overdose (Lin et al, 2012)
The observation that an acute, low dose of ethanol reversed
tolerance to the respiratory depressant effects of morphine
is in agreement with our previous studies in which we
demonstrated that a concentration of ethanol, which would
only be mildly intoxicating (20 mM) in man reversed
Figure 4 Effect of ethanol on morphine tolerance. (a, b) Administration of ethanol (0.3 g/kg) alone caused no significant depression of respiration in naive
mice or mice that had been implanted with a morphine pellet (MP) for 6 days. In 6 days, morphine pellet-implanted mice co-injection of ethanol (0.3 g/kg) and
morphine (10 mg/kg) resulted in significant depression of respiration compared to morphine pellet-implanted mice that received only a morphine injection
(F= 10.82, po0.001), whereas when ethanol (0.3 g/kg) was injected 6 h prior to the morphine challenge no depression of respiration by morphine was
observed. (c, d) No significant changes in locomotor activity were observed after any treatment. All drugs administered i.p. (other than pellet implantation).
Data are expressed as mean± SEM. In (b), two-way ANOVA with Bonferroni’s correction in a 2× 2 factorial was used; in (c, d) one-way ANOVA with
Bonferroni’s correction was used. *po0.05; N= 6 for all groups except in (b) for morphine 6 h after ethanol where N= 5.
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morphine-induced cellular tolerance (Llorente et al, 2013),
and that low doses of ethanol (0.01–1 g/kg i.p.) similar to that
used in the present study (0.3 g/kg i.p.) reversed tolerance
to the antinociceptive effects of morphine (Hull et al, 2013).
It is somewhat surprising that, after 6 days, ethanol injection
in morphine pellet-implanted mice did not by itself cause
respiratory depression by reversing tolerance to reveal the
respiratory depressant effect of the morphine still present in
the brain at that time. This may suggest that with long-term
exposure a significant amount of the drug is removed from
the extracellular space and becomes sequestered in brain
tissue such as membrane lipid and therefore is not available
for receptor activation.
In brain neurons, ethanol reversal of morphine cellular
tolerance was associated with a decrease in MOPr
desensitization. Ethanol also reduced MOPr phosphorylation
in response to morphine activation of the receptor.
This might suggest that ethanol reverses morphine tolerance
by directly inhibiting PKC activity but convincing
evidence for a direct inhibition of PKC by ethanol has been
hard to produce (Slater et al, 1997; Rex et al, 2008; Reneau
et al, 2011; Llorente et al, 2013). Alternatively, ethanol could
decrease MOPr phosphorylation and thus desensitization by
increasing phosphatase activity but this seems unlikely,
however, as we were unable to observe any effect of ethanol
on brain phosphatase activity (Llorente et al, 2013), and
others have reported that ethanol decreases rather than
increases protein phosphatase 2A activity (Hong-Brown
et al, 2007).
In the present study, prolonged methadone administration
induced tolerance to the respiratory depressant effects of
morphine—supporting observational evidence and clinical
guidance that suggest methadone can provide protection
against heroin-related overdose (Cornish et al, 2010;
Lingford-Hughes et al, 2012). Ethanol did not reverse tole-
rance to morphine induced by methadone. Different opioid
agonists desensitize the MOPr by different cellular mechan-
isms (Kelly et al, 2008). Methadone is a high-efficacy MOPr
agonist (Rodriguez-Martin et al, 2008) that actively recruits
arrestin to MOPr (McPherson et al, 2010), an effect that
requires prior phosphorylation of MOPr by G protein-
coupled receptor kinase (GRK) rather than PKC. Failure
of ethanol to reverse methadone-induced tolerance would
be compatible with the view that it induces tolerance by a
different mechanism to morphine.
Buprenorphine binds to MOPr with high affinity and
dissociates slowly. It is difficult to displace from the receptor
with other ligands, either agonists or antagonists (Lewis,
1985). The reduced response to morphine in buprenorphine-
pretreated mice could therefore result from either an
antagonist action of buprenorphine or the induction of
tolerance by buprenorphine. The experiments we conducted
cannot discriminate between these two possibilities. Which-
ever mechanisms is responsible for the subsequent reduced
response to morphine it is not reversed by ethanol.
One complicating factor that we have not yet studied is
how the effect on morphine tolerance might change with
chronic ethanol consumption. Chronic ethanol exposure has
been reported to reduce the coupling of the MOPr to
G proteins (Chen and Lawrence, 2000; Sim-Selley et al, 2002;
Saland et al, 2004) and reduce the antinociceptive effect of
morphine (He and Whistler, 2011). Thus the effects of acute
and chronic ethanol exposure could produce opposite effects
on morphine tolerance.
CONCLUSIONS
Our findings have profound implications for the under-
standing of opioid-related deaths and the role of alcohol
consumption. First, the results explain why the presence of
even only moderate amounts of ethanol in the blood can
have fatal consequences for opioid addicts who have injected
doses of heroin that would not otherwise be expected to lead
to overdose, but through reversal of tolerance to morphine-
induced respiratory depression rather than acting cumula-
tively to induce respiratory depression.
We also show that tolerance to the different effects of
opioid drugs develops at different rates. As originally
hypothesized by White and Irvine (1999) for respiratory
depression and euphoria: during dose escalation to maintain
responses that undergo rapid tolerance (euphoria), there is
Figure 5 Effect of ethanol on brain and plasma morphine levels. Brain levels (a) and plasma levels (b) of morphine in mice that had been implanted with a
75-mg morphine pellet for 6 days and then injected with either morphine (10 mg/kg)+ethanol (0.3 g/kg) or morphine (10 mg/kg)+saline 15 min before killing
the mice. Data are expressed as mean± SEM and were analyzed using Student’s unpaired t–test. N= 8 for all groups.
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an increased likelihood of severe adverse effects (eg, fatal
respiratory depression) for responses that undergo little or
slowly developing tolerance.
Finally, the fact that ethanol does not appear to reverse
tolerance to methadone and buprenorphine highlights the
fact that different opioids trigger distinct regulatory mechan-
isms in the brain (Kelly et al, 2008), and also underlines
the complexities and dangers of polypharmacy for addicts
who may or may not be taking maintenance therapies.
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